Thymic epithelial tumours: From basic principles to individualised treatment strategies

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 75-87

  Girard, Nicolas ^a  

^a LOUIS PRADEL HOSPITAL   (France)

Author keywords

Chemotherapy; Myasthenia gravis; Radiotherapy; Surgery; Thymic carcinoma; Thymoma

Indexed keywords

AFLIBERCEPT; BELINOSTAT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; METHYLPREDNISOLONE; MOTESANIB; NILOTINIB; PACLITAXEL; PEMETREXED; PREDNISONE; SORAFENIB; SUNITINIB; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MINIMALLY INVASIVE SURGERY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; RECURRENCE FREE SURVIVAL; SURGICAL APPROACH; SURVIVAL RATE; THORACOTOMY; THYMECTOMY; THYMIC EPITHELIAL TUMOR; THYMOMA; THYMUS CANCER; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATIENT SELECTION; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; SIGNAL TRANSDUCTION; THYMECTOMY; THYMUS NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84874722920     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007312     Document Type: Article

References (130)

1. de Jong WK, Blaauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44: 123-130.
2. Girard N, Mornex F, Van Houtte P, et al. Thymoma: a focus on current therapeutic management. J Thorac Oncol 2009; 4: 119-126.
3. Travis WB, Brambilla A, Muller-Hermelinck HK, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004; p. 146.
4. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004; 59: 654-664.
5. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994; 44: 359-367.
6. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76: 878-884.
7. Okumura M, Shiono H, Inoue M, et al. Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system. J Surg Oncol 2007; 95: 40-44.
8. Chalabreysse L, Roy P, Cordier JF, et al. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: a retrospective study of 90 tumors. Am J Surg Pathol 2002; 26: 1605-1611.
9. Rossi G, Costantini M, Tagliavini E, et al. Thymoma classifica- tion: does it matter? Histopathology 2008; 53: 483-484.
10. Weissferdt A, Moran CA. Thymic carcinoma, part 2: a clinicopathologic correlation of 33 cases with a proposed staging system. Am J Clin Pathol 2012; 138: 115-121.
11. Takahama Y. Journey through the thymus: stromal guides for T- cell development and selection. Nat Rev Immunol 2006; 6: 127-135.
12. Marx A, Hohenberger P, Hoffmann H, et al. The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 2010; 5: Suppl. 4, S266-S272.
13. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008; 22: 509-526.
14. Masaoka A, Yamakawa Y, Niwa H, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 1996; 62: 853-859.
15. Huang J, Detterbeck FC, Wang Z, et al. Standard outcome measures for thymic malignancies. J Thorac Oncol 2011; 6: Suppl. 3, S1691-S1697.
16. Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg 2008; 86: 673-684.
17. NCCN Clinical Practice Guidelines in Oncology. Thymic malignancies. V.2.2010. Available at www.nccn.org
18. Tomaszek S, Wigle DA, Keshavjee S, et al. Thymomas: review of current clinical practice. Ann Thorac Surg 2009; 87: 1973-8190.
19. Kong FM, Lu JJ. Thymoma. In: Brady LW, Lu JJ, Heilmann HP. Radiation Oncology: An Evidence-Based Approach. Berlin, Springer-Verlag, 2008; pp 159-170.
20. Falkson CB, Bezjak A, Darling G, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911-919.
21. Detterbeck F, Youssef S, Ruffini E, et al. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011; 6: Suppl. 3, S1698-S1704.
22. Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 2012; 12: 685-695.
23. Girard M, Lal R, Wakelee H, et al. Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol 2011; 6: Suppl. 3, S1749-S1755.
24. Detterbeck F, Nicholson AG, Kondo K, et al. The Masaoka-Koga Stage Classification for Thymic Malignancies: clarification and definition of terms. J Thoracic Oncol 2011; 6: Suppl. 3, S1710-S1716.
25. Rieker RJ, Muley T, Klein C, et al. An institutional study on thymomas and thymic carcinomas: experience in 77 patients. Thorac Cardiovasc Surg 2008; 56: 143-147.
26. Verghese ET, den Bakker MA, Campbell A, et al. Interobserver variation in the classification of thymic tumours - a multicentre study using the WHO classification system. Histopathology 2008; 53: 218-223.
27. Marom EM, Milito MA, Moran CA, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol 2011; 6: 1274-1281.
28. Kaira K, Murakami H, Miura S, et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 2011; 25: 247-253.
29. El-Bawab HY, Abouzied MM, Rafay MA, et al. Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence. Interact Cardiovasc Thorac Surg 2010; 11: 395-399.
30. Marchevsky A, Marx A, Ströbel P, et al. Policies and reporting guidelines for small biopsy specimens of mediastinal masses. J Thorac Oncol 2011; 6: Suppl. 3, S1724-S1729.
31. Detterbeck FC, Moran C, Huang J, et al. Which Way is Up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thoracic Oncol 2011; 6: Suppl. 3, S1730-S1738.
32. Kaiser LR. Surgical treatment of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008; 22: 475-488.
33. Toker A, Sonett J, Zielinski M, et al. Standard terms, definitions, and policies for minimally invasive resection of thymoma. J Thorac Oncol 2011; 6: Suppl. 3, S1739-S1742.
34. Rückert JC, Ismail M, Swierzy M, et al. Thoracoscopic thymectomy with the da Vinci robotic system for myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 329-335.
35. Cakar F, Werner P, Augustin F, et al. A comparison of outcomes after robotic and open extended thymectomy for myasthenia gravis. Eur J Cardiothorac Surg 2007; 31: 501-505.
36. Yellin A, Simansky DA, Ben-Avi R, et al. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg 2013; 145: 83-89.
37. Wright CD, Choi NC, Wain JC, et al. Induction chemoradio- therapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008; 85: 385-389.
38. Gomez D, Komaki R, Yu J, et al. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol 2011; 6: Suppl. 3, S1743-S1748.
39. Girard N, Mornex F. The role of radiotherapy in the management of thymic tumors. Thorac Surg Clin 2011; 21: 99-105.
40. Arriagada R, Bretel JJ, Caillaud JM, et al. Invasive carcinoma of the thymus. A multicenter retrospective review of 56 cases. Eur J Cancer Clin Oncol 1984; 20: 69-74.
41. Zhu G, He S, Fu X, et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys 2004; 60: 1113-1119.
42. Kadota Y, Utsumi T, Inoue M, et al. Radiation-induced osteosarcoma 17 years after mediastinal irradiation following surgical removal of thymoma. Gen Thorac Cardiovasc Surg 2010; 58: 651-653.
43. Zhang H, Lu N, Wang M, et al. Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases. Chin Med J (Engl) 1999; 112: 136-138.
44. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010; 76: 440-445.
45. Ruffini E, Van Raemdonck D, Detterbeck F, et al. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol 2011; 6: 614-623.
46. Curran WJ Jr, Kornstein MJ, Brooks JJ, et al. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 1988; 6: 1722-1727.
47. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999; 230: 562-572.
48. Kundel Y, Yellin A, Popovtzer A, et al. Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors. Am J Clin Oncol 2007; 30: 389-394.
49. Wu KL, Mao JF, Chen GY, et al. Prognostic predictors and long-term outcome of postoperative irradiation in thymoma: a study of 241 patients. Cancer Invest 2009; 27: 1008-1015.
50. Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. Ann Thorac Surg 2002; 74: 1033-1037.
51. Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 2002; 94: 1405-1413.
52. Fernandes AT, Shinohara ET, Guo M, et al. The role of radiation therapy in malignant thymoma: a Surveillance, Epidemiology, and End Results database analysis. J Thorac Oncol 2010; 5: 1454-1460.
53. Berman AT, Litzky L, Livolsi V, et al. Adjuvant radiotherapy for completely resected stage 2 thymoma. Cancer 2011; 117: 3502-3508.
54. Weksler B, Shende M, Nason KS, et al. The role of adjuvant radiation therapy for resected stage III thymoma: a population- based study. Ann Thorac Surg 2012; 93: 1822-1828.
55. Mornex F, Resbeut M, Richaud P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retro- spective review of 90 cases. The FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys 1995; 32: 651-659.
56. Myojin M, Choi NC, Wright CD, et al. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. Int J Radiat Oncol Biol Phys 2000; 46: 927-933.
57. Ciernik IF, Meier U, Lü tolf UM. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. J Clin Oncol 1994; 12: 1484-1490.
58. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J Thorac Cardiovasc Surg 1988; 95: 1041-1047.
59. Haniuda M, Morimoto M, Nishimura H, et al. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 1992; 54: 311-315.
60. Pollack A, Komaki R, Cox JD, et al. Thymoma: treatment and prognosis. Int J Radiat Oncol Biol Phys 1992; 23: 1037-1043.
61. Urgesi A, Monetti U, Rossi G, et al. Aggressive treatment of intrathoracic recurrences of thymoma. Radiother Oncol 1992; 24: 221-225.
62. Patel S, Macdonald OK, Nagda S, et al. Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys 2012; 82: 1797-1801.
63. Korst RJ, Kansler AL, Christos PJ, et al. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta- analysis. Ann Thorac Surg 2009; 87: 1641-1647.
64. Kim HK, Choi YS, Kim J, et al. Type B thymoma: is prognosis predicted only by World Health Organization classification? J Thorac Cardiovasc Surg 2010; 139: 1431-1435.
65. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009; 115: 5413-5420.
66. Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 2010; 78: 1400-1406.
67. Hsu HC, Huang EY, Wang CJ, et al. Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2002; 52: 801-805.
68. Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with stage II-III invasive thymoma. Int J Radiat Oncol Biol Phys 1996; 35: 357-360.
69. Yoshida H, Uematsu M, Itami J, et al. The role of low-dose hemithoracic radiotherapy for thoracic dissemination of thymoma. Radiat Med 1997; 15: 399-403.
70. Sugie C, Shibamoto Y, Ikeya-Hashizume C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac Oncol 2008; 3: 75-81.
71. Attaran S, Acharya M, Anderson JR, et al. Does surgical debulking for advanced stages of thymoma improve survival? Interact Cardiovasc Thorac Surg 2012; 15: 494-497.
72. Loehrer PJ Sr, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited- stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997; 15: 3093-3099.
73. Sur RK, Pacella JA, Donde B, et al. Role of radiotherapy in stage III invasive thymomas. S Afr J Surg 1997; 35: 206-209.
74. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, fol- lowed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44: 369-379.
75. Attaran S, McCormack D, Pilling J, et al. Which stages of thy- moma benefit from adjuvant chemotherapy post-thymectomy? Interact Cardiovasc Thorac Surg 2012; 15: 273-275.
76. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single- institution experience. Am J Clin Oncol 2004; 27: 68-72.
77. Kitami A, Suzuki T, Kamio Y, et al. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J Clin Oncol 2001; 31: 601-604.
78. Macchiarini P, Chella A, Ducci F, et al. Neoadjuvant chemo- therapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 1991; 68: 706-713.
79. Berruti A, Borasio P, Roncari A, et al. Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclopho- sphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 1993; 4: 429-431.
80. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993; 106: 543-549.
81. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81: 841-845.
82. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003; 76: 1866-1872.
83. Bretti S, Berruti A, Loddo C, et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 2004; 44: 69-77.
84. Lucchi M, Ambrogi MC, Duranti L, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005; 79: 1840-1844.
85. Jacot W, Quantin X, Valette S, et al. Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 2005; 28: 5-7.
86. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007; 2: 73-78.
87. Kunitoh H, Tamura T, Shibata T, et al. A phase II trial of dose- dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 2010; 103: 6-11.
88. Park S, Park K, Ahn M, et al. A prospective phase II trial of induction chemotherapy with docetaxel cisplatin for Masaoka stage III/IV thymic epithelial tumors. J Clin Oncol 2012; 30: Suppl. 7104.
89. Craven C, Reddy PK, Ringel SP, et al. Effect of corticosteroids on the thymus in myasthenia gravis. Muscle Nerve 1981; 4: 425-428.
90. Bonomi PD, Finkelstein D, Aisner S, et al. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16: 342-345.
91. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999; 17: 2737-2744.
92. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006; 24: 7079.
93. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8: 1419-1423.
94. Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12: 1164-1168.
95. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814-820.
96. Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001; 91: 2010-2015.
97. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29: 2060-2065.
98. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010; 21: 1168-1172.
99. Okuma Y, Hosomi Y, Takagi Y, et al. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 2011; 74: 492-496.
100. Lara PN Jr, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclo- phosphamide. Chest 1996; 110: 1115-1117.
101. Lucchi M, Mussi A. Surgical treatment of recurrent thymomas. J Thorac Oncol 2010; 5: Suppl. 4, S348-S351.
102. Huang J, Rizk NP, Travis WD, et al. Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 2009; 138: 26-31.
103. Bae MK, Byun CS, Lee CY, et al. Clinical outcomes and prognosis of recurrent thymoma management. J Thorac Oncol 2012; 7: 1304-1314.
104. Hamaji M, Allen MS, Cassivi SD, et al. The role of surgical management in recurrent thymic tumors. Ann Thorac Surg 2012; 94: 247-254.
105. Bott MJ, Wang H, Travis W, et al. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. Ann Thorac Surg 2011; 92: 1984-1991.
106. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293-299.
107. Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002; 94: 1414-1420.
108. Schalke B, Boy S, Hofmann HS, et al. Neoadjuvant treatment of primary inoperable or local recurrent thymoma with octreotide LAR to improve tumor resectability. J Clin Oncol 2012; 30: Suppl., 7105.
109. Girard N, Teruya-Feldstein J, Payabyab EC, et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010; 5: 1439-1446.
110. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008; 22: 443-455.
111. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004; 130: 222-224.
112. Ströbel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004; 350: 2625-2626.
113. Li XF, Chen Q, Huang WX, et al. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 2009; 26: 157-160.
114. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009; 4: 773-775.
115. Dişel U, Oztuzcu S, Beşen AA, et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 2011; 71: 109-112.
116. Buti S, Donini M, Sergio P, et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol 2011; 29: e803-e805.
117. Schirosi L, Nannini N, Nicoli D, et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol 2012; 23: 2409-2414.
118. Palmieri G, Marino M, Buonerba C, et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol 2012; 69: 309-315.
119. Giaccone G, Rajan A, Ruijter R, et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009; 4: 1270-1273.
120. Salter JT, Lewis D, Yiannoutsos C, et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008; 26: 8116.
121. Cimpean AM, Raica M, Encica S, et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008; 190: 238-245.
122. Marino M, Piantelli M. Immunohistochemistry of thymic epithelial tumors as a tool in translational research. J Thorac Surg Clin 2011; 21: 33-46.
123. Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002; 124: 493-498.
124. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008; 26: Suppl., 19087.
125. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008; 26: Suppl., 3599.
126. Chuah C, Lim TH, Lim AS, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: e56-e58.
127. Ströbel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010; 103: 196-200.
128. Azad A, Herbertson RA, Pook D, et al. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol 2009; 48: 619-621.
129. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 2011; 29: 2052-2059.
130. Rajan A, Berman AW, Kelly RJ, et al. Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutu- mumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC). J Clin Oncol 2010; 28: Suppl., e17525.